ATOS earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -0.56. Updated 2026-07-23.
Atossa Therapeutics (ATOS) Research Hub
Atossa Therapeutics (ATOS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.45 USD (-5.77%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.56, market cap 0.02B. This hub links to the full technical, earnings and options research available for ATOS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.45 USD (-5.77%) |
| 52-week range | 1.73 USD – 3.095 USD |
| Trend regime | Range |
| 14-day RSI | 50 (Neutral) |
| Trailing P/E | -0.56 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ATOS
Covered Call on ATOS: how it works, illustrative setup around the real 2.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ATOS: how it works, illustrative setup around the real 2.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ATOS: how it works, illustrative setup around the real 2.45 USD price, max profit/loss, breakeven and when to use it. Educational.
ATOS technical analysis: range, last 2.45 USD, RSI 50, 52w range 1.73 USD–3.095 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ATOS in?
Atossa Therapeutics (ATOS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ATOS in an uptrend or downtrend?
As of 2026-10-26, ATOS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ATOS's trailing P/E ratio?
ATOS's trailing P/E is -0.56, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does ATOS next report earnings?
ATOS is next scheduled to report earnings on 2026-08-11.